Alexandra Lansky

List of Publications by Year
in descending order

187 papers	23,243 citations	23500 58 h-index	7718 150 g-index
189 all docs	189 docs citations	189 times ranked	13784 citing authors

#	Article	IF	Citations
1	Clinical End Points in Coronary Stent Trials. Circulation, 2007, 115, 2344-2351.	1.6	4,993
2	Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine, 2012, 367, 2375-2384.	13.9	1,573
3	Angiographic Patterns of In-Stent Restenosis. Circulation, 1999, 100, 1872-1878.	1.6	1,151
4	Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms. Journal of the American College of Cardiology, 2011, 58, 1989-1997.	1.2	1,058
5	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal of Medicine, 2010, 362, 1663-1674.	13.9	812
6	Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery. Circulation: Cardiovascular Interventions, 2010, 3, 267-276.	1.4	586
7	Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 293, 1063.	3.8	508
8	Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery:Long-term Results From the SIROCCO Trial. Journal of Endovascular Therapy, 2006, 13, 701-710.	0.8	468
9	Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease. Circulation, 2002, 106, 1505-1509.	1.6	445
10	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. European Heart Journal, 2007, 28, 1709-1716.	1.0	411
11	Diagnostic Accuracy of Fast Computational Approaches to DeriveÂFractional Flow Reserve FromÂDiagnostic Coronary Angiography. JACC: Cardiovascular Interventions, 2016, 9, 2024-2035.	1.1	394
12	Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. Journal of Vascular and Interventional Radiology, 2005, 16, 331-338.	0.2	386
13	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal, 2020, 41, 3504-3520.	1.0	385
14	Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 591-597.	1.2	370
15	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
16	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet, The, 2007, 369, 907-919.	6.3	367
17	Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. Circulation, 2003, 108, 2769-2775.	1.6	361
18	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	1.2	343

#	Article	IF	Citations
19	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	1.1	329
20	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal, 2009, 30, 1457-1466.	1.0	315
21	Intracoronary Î²-Radiation Therapy Inhibits Recurrence of In-Stent Restenosis. Circulation, 2000, 101, 1895-1898.	1.6	304
22	Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. Journal of Endovascular Therapy, 2012, 19, 1-9.	0.8	266
23	A prospective randomized evaluation of the TriGuardâ„¢ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. European Heart Journal, 2015, 36, 2070-2078.	1.0	259
24	Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. Circulation, 2000, 101, 604-610.	1.6	256
25	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal, 2004, 148, 764-775.	1.2	231
26	Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S62-S72.	2.3	231
27	Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses. Circulation, 2019, 139, 834-836.	1.6	226
28	Creatine Kinase-MB Enzyme Elevation Following Successful Saphenous Vein Graft Intervention Is Associated With Late Mortality. Circulation, 1999, 100, 2400-2405.	1.6	217
29	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	1.2	211
30	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
31	Usefulness of a cobalt chromium coronary stent alloy. American Journal of Cardiology, 2003, 92, 463-466.	0.7	190
32	Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 914-922.	1.1	181
33	Sex Differences in Long-Term Mortality After Myocardial Infarction. Circulation, 2014, 130, 757-767.	1.6	178
34	Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation, 2005, 111, 1611-1618.	1.6	173
35	Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 305-312.	1.2	171
36	Effect of gender on the outcomes of contemporary percutaneous coronary intervention. American Journal of Cardiology, 2001, 88, 359-364.	0.7	157

#	Article	IF	Citations
37	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. Journal of the American College of Cardiology, 2008, 51, 23-32.	1.2	153
38	The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal, 2008, 156, 44-56.	1.2	152
39	Periprocedural Myocardial Infarction. Circulation: Cardiovascular Interventions, 2010, 3, 602-610.	1.4	139
40	Long-Term Outcome of PCI Versus CABGÂin Insulin and Nonâ€“Insulin-Treated Diabetic Patients. Journal of the American College of Cardiology, 2014, 64, 1189-1197.	1.2	134
41	Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events. JACC: Cardiovascular Imaging, 2018, 11, 462-471.	2.3	124
42	Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheterization and Cardiovascular Interventions, 2019, 93, 335-342.	0.7	120
43	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 1209-1215.	1.1	115
44	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. Journal of the American College of Cardiology, 2017, 69, 679-691.	1.2	110
45	Safety and Performance ofÂLithoplasty for Treatment of Calcified Peripheral Artery Lesions. Journal of the American College of Cardiology, 2017, 70, 908-910.	1.2	96
46	Mechanism of Lumen Enlargement During Intracoronary Stent Implantation. Circulation, 2000, 102, 7-10.	1.6	94
47	Rheolytic thrombectomy in the treatment of acute limb-threatening ischemia: Immediate results and six-month follow-up of the multicenter AngioJetÂ® registry. , 1998, 45, 386-393.		93
48	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31â€…379 patients. Open Heart, 2014, 1, e000064.	0.9	88
49	Usefulness of Noninvasive Fractional Flow Reserve Computed from Coronary Computed Tomographic Angiograms for Intermediate Stenoses Confirmed by Quantitative Coronary Angiography. American Journal of Cardiology, 2012, 110, 971-976.	0.7	85
50	Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. American Journal of Cardiology, 2001, 87, 157-162.	0.7	82
51	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	1.0	80
52	Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. American Journal of Cardiology, 2001, 87, 152-156.	0.7	72
53	Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 52, 807-814.	1.2	72
54	Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	0.7	72

#	Article	IF	Citations
55	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	1.2	70
56	Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. Journal of Endovascular Therapy, 2020, 27, 473-480.	0.8	67
57	Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies. JACC: Cardiovascular Interventions, 2009, 2, 748-757.	1.1	66
58	Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. Circulation, 2011, 123, 2829-2837.	1.6	62
59	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. Circulation, 1998, 97, 1355-1361.	1.6	61
60	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention, 2013, 9, 75-83.	1.4	60
61	Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention, 2015, 11, 75-84.	1.4	58
62	Local delivery of paclitaxel in the treatment of peripheral arterial disease. European Journal of Clinical Investigation, 2015, 45, 333-345.	1.7	54
63	Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 515-527.	1.1	53
64	The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System. Circulation, 2015, 132, 1710-1718.	1.6	52
65	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 2309-2316.	1.2	49
66	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet, The, 2018, 392, 1117-1126.	6.3	46
67	Procedural results and late clinical outcomes after percutaneous interventions using long (â‰¥25 mm) versus short (<20 mm) stents. Journal of the American College of Cardiology, 2000, 35, 612-618.	1.2	45
68	Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 372-379.	1.1	45
69	The DENALI Trial: An Interim Analysis of a Prospective, Multicenter Study of the Denali Retrievable Inferior Vena Cava Filter. Journal of Vascular and Interventional Radiology, 2014, 25, 1497-1505.e1.	0.2	43
70	Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	39
71	A randomized evaluation of the TriGuardâ„¢ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal, 2021, 42, 2670-2679.	1.0	39
72	Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal, 2012, 163, 383-391.e5.	1.2	38

#	Article	IF	Citations
73	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal, 2018, 39, 1687-1697.	1.0	38
74	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)â€“2 trial. American Heart Journal, 2006, 151, 1032.e1-1032.e7.	1.2	37
75	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	33
76	Sex Disparities in Cardiovascular DeviceÂEvaluations. JACC: Cardiovascular Interventions, 2019, 12, 301-308.	1.1	34
77	Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 147, 23-32.	0.7	34
78	First-in-Human Evaluation of a Bioabsorbable Polymerâ€“Coated Sirolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2013, 6, 1026-1034.	1.1	32
79	A prospective, multiâ€center study of the chocolate balloon in femoropopliteal peripheral artery disease: The <scp>C</scp>hocolate <scp>BAR</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 91, 1144-1148.	0.7	31
80	Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clinical Cardiology, 2019, 42, 974-981.	0.7	31
81	Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). American Journal of Cardiology, 2016, 118, 396-402.	0.7	30
82	Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). American Journal of Cardiology, 2016, 117, 186-191.	0.7	30
83	Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. EuroIntervention, 2015, 10, 1383-1390.	1.4	30
84	Novel QCA methodologies and angiographic scores. International Journal of Cardiovascular Imaging, 2011, 27, 157-165.	0.7	28
85	Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic Journal of Cardiology, 2021, 62, 374-377.	0.4	28
86	A pooled gender based analysis comparing the XIENCE VÂ® everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention, 2010, 5, 788-794.	1.4	28
87	A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial. American Heart Journal, 2012, 164, 320-326.	1.2	27
88	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. JACC: Cardiovascular Imaging, 2020, 13, 2206-2219.	2.3	27
89	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheterization and Cardiovascular Interventions, 2001, 54, 295-300.	0.7	25
90	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis, 2014, 233, 224-231.	0.4	25

#	Article	IF	Citations
91	Treating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System. JACC: Cardiovascular Interventions, 2019, 12, 2375-2384.	1.1	25
92	Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter. Journal of Vascular and Interventional Radiology, 2016, 27, 1531-1538.e1.	0.2	24
93	Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	23
94	Implications of ventricular arrhythmia â€œburstsâ€• with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: A biosignature of direct myocellular injury â€œdownstream of downstreamâ€• European Heart Journal: Acute Cardiovascular Care, 2015, 4, 51-59.	0.4	23
95	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal of Endovascular Therapy, 2018, 25, 68-78.	0.8	23
96	Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf American Journal of Cardiology, 2014, 113, 930-935.	0.7	22
97	Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 527-534.	0.9	22
98	Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention, 2010, 6, J44-J52.	1.4	22
99	Clinical implications for diffusionâ€•weighted MRI brain lesions associated with transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2014, 83, 502-508.	0.7	21
100	Wall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve. Atherosclerosis, 2021, 322, 24-30.	0.4	21
101	Evaluation of the effects of everolimusâ€•eluting and paclitaxelâ€•eluting stents on target lesions with jailed side branches: 2â€•year results from the SPIRIT III randomized trial. Catheterization and Cardiovascular Interventions, 2010, 76, 644-651.	0.7	20
102	Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. American Journal of Cardiology, 2012, 110, 21-29.	0.7	20
103	Optical coherence tomography enables more accurate detection of functionally significant intermediate non-left main coronary artery stenoses than intravascular ultrasound: A meta-analysis of 6919 patients and 7537 lesions. International Journal of Cardiology, 2020, 301, 226-234.	0.8	19
104	Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheterization and Cardiovascular Interventions, 2000, 50, 245-254.	0.7	18
105	Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization and Cardiovascular Interventions, 2017, 89, 984-991.	0.7	18
106	Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2020, 5, 92.	3.0	18
107	Predictors of Underutilization of MedicalÂTherapy in Patients Undergoing Endovascular Revascularization for Peripheral Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 2911-2918.	1.1	18
108	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). American Journal of Cardiology, 2016, 117, 532-538.	0.7	17

#	Article	IF	Citations
109	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents) Tj ETQq1 1 0.784314 rgBT /Overlo	0.7	8
110	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. Circulation, 2021, 143, 2143-2154.	1.6	16
111	Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. JACC: Cardiovascular Interventions, 2021, 14, 2083-2096.	1.1	15
112	2-Year Clinical Outcomes of anÂAbluminal Grooveâ€"Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2019, 12, 1679-1687.	1.1	14
113	Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit. BMC Medicine, 2013, 11, 257.	2.3	13
114	Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions. JACC: Cardiovascular Interventions, 2018, 11, 517-528.	1.1	13
115	Computerised Methodologies for Non-Invasive Angiography-Derived Fractional Flow Reserve Assessment: A Critical Review. Journal of Interventional Cardiology, 2020, 2020, 1-10.	0.5	13
116	Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention, 2011, 7, 307-313.	1.4	13
117	Revascularization Options for Females With Multivessel Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1009-1010.	1.1	12
118	Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation, 2022, 145, 1645-1654.	1.6	12
119	Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis. European Heart Journal, 2020, 41, 3729-3731.	1.0	11
120	Low Stent Thrombosis Risk with the XIENCE VÂ® Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. Journal of Interventional Cardiology, 2011, 24, 326-341.	0.5	10
121	Safety and efficacy of a novel abluminal grooveâ€filled biodegradable polymer sirolimusâ€eluting stent for the treatment of de novo coronary lesions: Twoâ€year results from a prospective patientâ€level pooled analysis of TARGET trials. Catheterization and Cardiovascular Interventions, 2015, 85, 734-743.	0.7	10
122	Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs, 2021, 81, 1381-1395.	4.9	10
123	Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent. Medical Devices: Evidence and Research, 2014, 7, 149.	0.4	9
124	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. American Journal of Cardiology, 2016, 118, 6-16.	0.7	9
125	Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 1026.	1.3	9
126	Importance of lesion length on new device angioplasty of native coronary arteries. Catheterization and Cardiovascular Interventions, 2000, 50, 19-25.	0.7	8

#	Article	IF	Citations
127	Fractional Flow Reserve From 3-Dimensional Quantitative Coronary Angiography. JACC: Cardiovascular Interventions, 2014, 7, 778-780.	1.1	8
128	Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 251-257.	0.7	8
129	Frequency of Management of Cardiogenic Shock With Mechanical Circulatory Support Devices According to Race. American Journal of Cardiology, 2020, 125, 1782-1787.	0.7	8
130	Understanding neurologic complications following TAVI. Interventional Cardiology Review, 2017, 13, 27.	0.7	8
131	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.7	8
132	Prognostic utility of myocardial blush grade after PCI in patients with NSTEâ€ACS: Analysis from the ACUITY trial. Catheterization and Cardiovascular Interventions, 2016, 88, 215-224.	0.7	6
133	What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2017, 50, 952-959.	0.4	6
134	Carotid Disease and Stroke After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006826.	1.4	6
135	Longâ€term serial functional evaluation after implantation of the Fantom sirolimusâ€eluting bioresorbable coronary scaffold. Catheterization and Cardiovascular Interventions, 2021, 97, 431-436.	0.7	6
136	Repurposing colchicineâ€™s journey in view of drug-to-drug interactions. A review. Toxicology Reports, 2021, 8, 1389-1393.	1.6	6
137	Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 98, E501-E512.	0.7	6
138	Long term outcomes of ultrathin versus standard thickness <scp>secondâ€generation</scp> drug eluting stents: <scp>Metaâ€analysis</scp> of randomized trials. Catheterization and Cardiovascular Interventions, 2022, 99, 563-574.	0.7	6
139	TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. EuroIntervention, 2018, 14, AB53-AB63.	1.4	6
140	Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention, 2010, 6, 437-446.	1.4	6
141	Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 577.	3.0	6
142	Diagnosing and Characterizing Coronary Artery Disease in Women: Developments in Noninvasive and Invasive Imaging Techniques. Journal of Cardiovascular Translational Research, 2013, 6, 740-751.	1.1	5
143	Bioabsorbable polymerâ€coated sirolimusâ€eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial subâ€study. Catheterization and Cardiovascular Interventions, 2015, 86, 1141-1150.	0.7	5
144	Coronary Microvascular Dysfunction. JACC: Cardiovascular Interventions, 2015, 8, 1442-1444.	1.1	5

#	Article	IF	Citations
145	Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial. International Journal of Cardiology, 2016, 207, 269-276.	0.8	5
146	Sex disparities in acute myocardial infarction care and outcomes. Catheterization and Cardiovascular Interventions, 2018, 92, E341-E347.	0.7	5
147	Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research and Clinical Practice, 2021, 174, 108724.	1.1	5
148	Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. EuroIntervention, 2020, 16, 787-793.	1.4	5
149	Health status outcomes after spontaneous coronary artery dissection and comparison with other acute myocardial infarction: The VIRGO experience. PLoS ONE, 2022, 17, e0265624.	1.1	5
150	Intracoronary brachytherapy not associated with changes in major side branches. Catheterization and Cardiovascular Interventions, 2000, 51, 154-158.	0.7	4
151	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary Clinical Trials, 2021, 110, 106547.	0.8	4
152	Computerized technologies informing cardiac catheterization and guiding coronary intervention. American Heart Journal, 2021, 240, 28-45.	1.2	4
153	Esc. Acta Cardiologica, 2014, 69, 100-108.	0.3	3
154	Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2016, 5, 523-532.	0.2	3
155	Clinical outcomes of complex lesions treated with an abluminal grooveâ€filled biodegradable polymer sirolimusâ€eluting stent and durable polymer everolimusâ€eluting stent. Catheterization and Cardiovascular Interventions, 2020, 96, 1023-1028.	0.7	3
156	The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. Cardiology in Review, 2020, 28, 208-212.	0.6	3
157	When a meta-analysis equals a single large-scale trial with meaningful follow-up. European Heart Journal, 2021, 42, 3884-3885.	1.0	3
158	Clinical outcome after interventions with paclitaxel-coated balloons: a PCR statement. EuroIntervention, 2020, 15, 1225-1227.	1.4	3
159	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: AÂPatient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
160	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 266-275.	1.1	2
161	Nineâ€month results of the BIOHELIXâ€I clinical trial study: Evaluation of the PROâ€Kinetic Energy cobalt chromium bareâ€metal stent system. Catheterization and Cardiovascular Interventions, 2018, 92, 1030-1039.	0.7	2
162	The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. Journal of Women's Health, 2019, 28, 728-735.	1.5	2

#	Article	IF	Citations
163	Cerebral Embolic Protection. JACC: Cardiovascular Interventions, 2020, 13, 2156-2158.	1.1	2
164	Refining drug-eluting stent technologies: from engineering to basic science. European Heart Journal, 2021, 42, 1770-1772.	1.0	2
165	Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheterization and Cardiovascular Interventions, 2022, 99, 263-270.	0.7	2
166	Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. Journal of Clinical Medicine, 2021, 10, 5128.	1.0	2
167	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
168	ST-Segment Elevation Myocardial Infarction: Sex Differences in Incidence, Etiology, Treatment, and Outcomes. Current Cardiology Reports, 2022, 24, 529-540.	1.3	2
169	Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2013, 11, 437-445.	0.6	1
170	ESC. Acta Cardiologica, 2014, 69, 435-445.	0.3	1
171	Seasonal variation in U.S. hospitalizations for chronic <scp>limbâ€threatening</scp> ischemia. Catheterization and Cardiovascular Interventions, 2020, 96, 1473-1480.	0.7	1
172	Sex-Specific Outcomes in Cardiovascular Device Evaluations. Journal of Women's Health, 2020, 29, 1246-1255.	1.5	1
173	Reduction of Cerebral Emboli: In vitro Study with a Novel Cerebral Embolic Protection Device . Medical Devices: Evidence and Research, 2020, Volume 13, 67-73.	0.4	1
174	Differential impact of abluminal <scp>grooveâ€filled biodegradableâ€polymer sirolimusâ€eluting</scp> stent versus <scp>durableâ€polymer everolimusâ€eluting</scp> stent on and off dual antiplatelet therapy. Catheterization and Cardiovascular Interventions, 2022, 99, 357-365.	0.7	1
175	Heroes, politics and media: the unshakable medical practice in the pandemic. European Heart Journal, 2021, 42, 2622-2625.	1.0	1
176	The Generations of Drug-Eluting Stents and Outcomes in Women. Interventional Cardiology Clinics, 2012, 1, 183-195.	0.2	0
177	Interventions for ST Elevation Myocardial Infarction in Women. Interventional Cardiology Clinics, 2012, 1, 453-465.	0.2	0
178	What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e003861.	1.4	0
179	Cerebral Embolic Protection: Pointâ€"Counter Point. Structural Heart, 2017, 1, 143-144.	0.2	0
180	First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2019, 12, 2568-2570.	1.1	0

#	Article	IF	Citations
181	Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal, 2020, 221, 148-154.	1.2	0
182	Cerebral Embolic Protection. JACC: Cardiovascular Interventions, 2020, 13, 869-871.	1.1	0
183	Characteristics of cardiac catheterization laboratory directors at the 2017 U.S. News & World Report top 100 U.S. cardiovascular hospitals. Catheterization and Cardiovascular Interventions, 2021, 97, E624-E626.	0.7	0
184	Embolic protection devices for stroke prevention during cardiac interventions. , 2020, , 941-960.		0
185	The â€œnitinol-constrainedâ€•Chocolate balloon angioplasty: clinical applications in patients with severe atherosclerotic peripheral arterial disease. , 2022, , 673-688.		0
186	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. , 2022, 1, 100033.		0
187	Almanac 2013: acute coronary syndromes. Turk Kardiyoloji Dernegi Arsivi, 2013, 41, 755-64.	0.6	0